Document is current
Any future updates will be listed below
-
Authors
Mangiafico, Salvatore P.
Tuo, Qing-Zhang
Li, Xiao-Lan
Liu, Yu
Haralambous, Christian
Ding, Xu-Long
Ayton, Scott https://orcid.org/0000-0002-3479-2427
Wang, Qing
Laybutt, D. Ross
Chan, Jeng Yie
Zhang, Xiang
Kos, Cameron https://orcid.org/0000-0002-6242-5990
Thomas, Helen E.
Loudovaris, Thomas
Yang, Chieh-Hsin
Joannides, Christos N. https://orcid.org/0000-0001-9034-4154
Lamont, Benjamin J.
Dai, Lunzhi https://orcid.org/0000-0002-3003-8910
He, Hai-Huai
Dong, Biao
Andrikopoulos, Sofianos
Bush, Ashley I. https://orcid.org/0000-0001-8259-9069
Lei, Peng https://orcid.org/0000-0001-5652-1962
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81722016, 82071191)
Department of Health | National Health and Medical Research Council
- License Information
-
More Information
Article History
Received: 3 February 2023
Revised: 5 September 2023
Accepted: 11 September 2023
First Online: 21 September 2023
Competing interests
: AIB is a shareholder in Alterity Ltd, Cogstate Ltd, Eucalyptus Pty Ltd, and Mesoblast Ltd. He is a paid consultant for and has a profit share interest in, Collaborative Medicinal Development Pty Ltd. All other authors declare that they have no competing interests.
